Last reviewed · How we verify
NCT03747081
Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
Phase 1, PHASE2 trial testing Rivaroxaban in Cerebral Venous Thrombosis in 50 participants. Status unknown.
1 January 2020
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 September 2018 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 May 2020 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Rivaroxaban (rivaroxaban) — full drug profile →
- Warfarin (warfarin) — full drug profile →
Conditions studied
- Cerebral Venous Thrombosis — all drugs for Cerebral Venous Thrombosis →
Sponsor
Isfahan University of Medical Sciences
Who can join
18 and older, any sex, with Cerebral Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With regard to Cerebral Venous Thrombosis (CVT) importance as a life threatening disease, specific care is necessary, Known anti-coagulants have limitations.Vitamin K antagonists such as Warfarin, require laboratory monitoring and exact administration starting and maintenance dose. although Rivaroxaban(selective and direct Xa factor antagonist ) has no monitoring and no drug interaction. This study aim to focus on efficacy of Warfarin versus Rivaroxaban.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comparison of Novel Oral Anticoagulants and Vitamin K Antagonists in Patients With Cerebral Venous Sinus Thrombosis on Efficacy and Safety: A Systematic Review.
Li H, Yao M, Liao S, Chen J, et al · · 2020 · cited 12× · PMID 33362699 · DOI 10.3389/fneur.2020.597623 -
Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study.
Khorvash F, Farajpour-Khanaposhtani MJ, Hemasian H, Saadatnia SM. · · 2021 · cited 11× · PMID 38011461 · DOI 10.18502/cjn.v20i3.7687 -
Efficacy and Safety of Direct Oral Anticoagulants in Cerebral Venous Thrombosis: Meta-Analysis of Randomized Clinical Trials.
Chen X, Guo L, Lin M. · · 2024 · cited 3× · PMID 38772568 · DOI 10.1177/10760296241256360 -
Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?
Mathew C, Zumberg M. · · 2021 · cited 3× · PMID 34889369 · DOI 10.1182/hematology.2021000319
Verify or expand the search:
- PubMed search for NCT03747081
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban
Trials testing the same drug.
- NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
- NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
- NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting
Other recruiting trials for Cerebral Venous Thrombosis
Currently open trials in the same condition.
- NCT07352358 — Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis · Phase 4 · recruiting
- NCT06947707 — Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients · recruiting
- NCT06531122 — Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis · Phase 3 · recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03747081 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 20 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03747081.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing